1. Home
  2. DNN vs IBRX Comparison

DNN vs IBRX Comparison

Compare DNN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Denison Mines Corp (Canada)

DNN

Denison Mines Corp (Canada)

HOLD

Current Price

$2.57

Market Cap

2.3B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.09

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNN
IBRX
Founded
1954
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
DNN
IBRX
Price
$2.57
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.71
AVG Volume (30 Days)
47.1M
12.6M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,493,456.00
$82,555,000.00
Revenue This Year
$197.29
$667.18
Revenue Next Year
$55.12
$88.32
P/E Ratio
N/A
N/A
Revenue Growth
23.35
1025.95
52 Week Low
$1.08
$1.83
52 Week High
$3.42
$4.27

Technical Indicators

Market Signals
Indicator
DNN
IBRX
Relative Strength Index (RSI) 47.59 43.96
Support Level $2.48 $2.06
Resistance Level $2.64 $2.50
Average True Range (ATR) 0.14 0.15
MACD -0.01 -0.01
Stochastic Oscillator 25.00 6.82

Price Performance

Historical Comparison
DNN
IBRX

About DNN Denison Mines Corp (Canada)

Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: